Matches in SemOpenAlex for { <https://semopenalex.org/work/W4317778918> ?p ?o ?g. }
- W4317778918 abstract "Fatigue is the most commonly reported symptom in people with advanced cancer. Cancer-related fatigue (CRF) is pervasive and debilitating, and can greatly impact quality of life (QoL). CRF has a highly variable clinical presentation, likely due to a complex interaction of multiple factors. Corticosteroids are commonly used to improve CRF, but the benefits are unclear and there are significant adverse effects associated with long-term use. With the increasing survival of people with metastatic cancer, the long-term effects of medications are becoming increasingly relevant. Since the impact of CRF can be immensely debilitating and can negatively affect QoL, its treatment warrants further review.To determine the benefits and harms of corticosteroids compared with placebo or an active comparator in adults with advanced cancer and CRF.We searched CENTRAL, MEDLINE, Embase, CINAHL, Science Citation Index (ISI Web of Science), LILACS, and two clinical trial registries from inception to 18 July 2022. SELECTION CRITERIA: We included randomised controlled trials in adults aged ≥18 years. We included participants with advanced cancer who were suffering from CRF. We included trials that randomised participants to corticosteroids at any dose, by any route, administered for the relief of CRF; compared to placebo or an active comparator, including supportive care or non-pharmacological treatments.Three review authors independently assessed titles identified by the search strategy; two review authors assessed risk of bias; and two extracted data. We extracted the primary outcome of participant-reported fatigue relief using validated scales and secondary outcomes of adverse events, serious adverse events and QoL. We calculated the risk ratio with 95% confidence intervals (CIs) between groups for dichotomous outcomes. We measured arithmetic mean and standard deviation, and reported the mean difference (MD) with 95% CI between groups for continuous outcomes. We used standardised mean difference (SMD) with 95% CIs when an outcome was measured with different instruments measuring the same construct. We used a random-effects model to meta-analyse the outcome data. We rated the certainty of the evidence using GRADE and created two summary of findings tables. MAIN RESULTS: We included four studies with 297 enroled participants; data were available for only 239 participants. Three studies compared corticosteroid (equivalent ≤ 8 mg dexamethasone) to placebo. One study compared corticosteroid (dexamethasone 4 mg) to an active comparator (modafinil 100 mg). There were insufficient data to evaluate subgroups, such as dose and duration of treatment. One study had a high risk of performance and detection bias due to lack of blinding, and one study had a high risk of attrition bias. Otherwise, we assessed risks of bias as low or unclear. Comparison 1: corticosteroids compared with placebo Participant-reported fatigue relief The was no clear difference between corticosteroids and placebo (SMD -0.46, 95% CI -1.07 to 0.14; 3 RCTs, 165 participants, very low-certainty evidence) for relief of fatigue at one week of the intervention. We downgraded the certainty of the evidence three times for study limitations due to unclear risk of bias, imprecision, and inconsistency. Adverse events There was no clear difference in the occurrence of adverse events between groups, but the evidence is very uncertain (3 RCTs, 165 participants; very low-certainty evidence). Serious adverse events There was no clear difference in the occurrence of serious adverse events between groups, but the evidence is very uncertain (2 RCTs, 118 participants; very low-certainty evidence). Quality of lIfe One study reported QoL at one week using the Edmonton Symptom Assessment System (ESAS) well-being, and found no clear difference in QoL between groups (MD -0.58, 95% CI -1.93 to 0.77). Another study measured QoL using the Quality of Life Questionnaire for Cancer Patients Treated with Anticancer Drugs (QoL-ACD), and found no clear difference between groups. There was no clear difference between groups for either study, but the evidence is very uncertain (2 RCTs, 118 participants; very low-certainty evidence). Comparison 2: corticosteroids compared with active comparator (modafinil) Participant-reported fatigue relief There was improvement in fatigue from baseline to two weeks in both groups (modafinil MD 10.15, 95% CI 7.43 to 12.87; dexamethasone MD 9.21, 95% CI 6.73 to 11.69), however no clear difference between the two groups (MD -0.94, 95% CI -4.49 to 2.61; 1 RCT, 73 participants, very low-certainty evidence). We downgraded the certainty of the evidence three times for very serious study limitations and imprecision. Adverse events There was no clear difference in the occurrence of adverse events between groups, but the evidence is very uncertain (1 RCT, 73 participants; very low-certainty evidence). Serious adverse events There were no serious adverse events reported in either group (1 RCT, 73 participants; very low-certainty evidence). Quality of lIfe One study measured QoL at two weeks, using the ESAS-well-being. There was marked improvement in QoL from baseline in both groups (modafinil MD -2.43, 95% CI -2.88 to -1.98; dexamethasone MD -2.16, 95% CI -2.68 to -1.64), however no clear difference between the two groups (MD 0.27, 95% CI -0.39 to 0.93; 1 RCT, 73 participants, very low-certainty evidence).There is insufficient evidence to support or refute the use of systemic corticosteroids in adults with cancer and CRF. We included four small studies that provided very low-certainty of evidence for the efficacy of corticosteroids in the management of CRF. Further high-quality randomised controlled trials with larger sample sizes are required to determine the effectiveness of corticosteroids in this setting." @default.
- W4317778918 created "2023-01-24" @default.
- W4317778918 creator A5020828104 @default.
- W4317778918 creator A5028084787 @default.
- W4317778918 creator A5039581973 @default.
- W4317778918 creator A5044876586 @default.
- W4317778918 creator A5045777210 @default.
- W4317778918 creator A5069828492 @default.
- W4317778918 creator A5084042135 @default.
- W4317778918 date "2023-01-23" @default.
- W4317778918 modified "2023-09-26" @default.
- W4317778918 title "Corticosteroids for the management of cancer-related fatigue in adults with advanced cancer" @default.
- W4317778918 cites W1494692328 @default.
- W4317778918 cites W1525436179 @default.
- W4317778918 cites W155395871 @default.
- W4317778918 cites W1583133215 @default.
- W4317778918 cites W1694807285 @default.
- W4317778918 cites W1891088877 @default.
- W4317778918 cites W1940235639 @default.
- W4317778918 cites W1952315861 @default.
- W4317778918 cites W1965690008 @default.
- W4317778918 cites W1967316449 @default.
- W4317778918 cites W1972479281 @default.
- W4317778918 cites W1973341557 @default.
- W4317778918 cites W1983769010 @default.
- W4317778918 cites W1993262172 @default.
- W4317778918 cites W1993714077 @default.
- W4317778918 cites W2018992654 @default.
- W4317778918 cites W2026792308 @default.
- W4317778918 cites W2064317905 @default.
- W4317778918 cites W2066823109 @default.
- W4317778918 cites W2071774307 @default.
- W4317778918 cites W2091917093 @default.
- W4317778918 cites W2098977651 @default.
- W4317778918 cites W2111859880 @default.
- W4317778918 cites W2113912115 @default.
- W4317778918 cites W2137586470 @default.
- W4317778918 cites W2145857111 @default.
- W4317778918 cites W2149321427 @default.
- W4317778918 cites W2150471053 @default.
- W4317778918 cites W2153616752 @default.
- W4317778918 cites W2156098321 @default.
- W4317778918 cites W2156189207 @default.
- W4317778918 cites W2161644052 @default.
- W4317778918 cites W2161943291 @default.
- W4317778918 cites W2167090973 @default.
- W4317778918 cites W2167352406 @default.
- W4317778918 cites W2177704039 @default.
- W4317778918 cites W2219732327 @default.
- W4317778918 cites W2247146814 @default.
- W4317778918 cites W2299365443 @default.
- W4317778918 cites W246286872 @default.
- W4317778918 cites W2523960744 @default.
- W4317778918 cites W2593266874 @default.
- W4317778918 cites W2802547370 @default.
- W4317778918 cites W2810384014 @default.
- W4317778918 cites W2889646458 @default.
- W4317778918 cites W2902649431 @default.
- W4317778918 cites W2913993799 @default.
- W4317778918 cites W2990783514 @default.
- W4317778918 cites W3011992252 @default.
- W4317778918 cites W3017286951 @default.
- W4317778918 cites W3123539216 @default.
- W4317778918 cites W3134491670 @default.
- W4317778918 cites W3134510203 @default.
- W4317778918 cites W3206305780 @default.
- W4317778918 cites W3213466944 @default.
- W4317778918 cites W4254264454 @default.
- W4317778918 cites W4294215472 @default.
- W4317778918 cites W4295992422 @default.
- W4317778918 cites W4295992460 @default.
- W4317778918 cites W2255751957 @default.
- W4317778918 doi "https://doi.org/10.1002/14651858.cd013782.pub2" @default.
- W4317778918 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36688471" @default.
- W4317778918 hasPublicationYear "2023" @default.
- W4317778918 type Work @default.
- W4317778918 citedByCount "0" @default.
- W4317778918 crossrefType "journal-article" @default.
- W4317778918 hasAuthorship W4317778918A5020828104 @default.
- W4317778918 hasAuthorship W4317778918A5028084787 @default.
- W4317778918 hasAuthorship W4317778918A5039581973 @default.
- W4317778918 hasAuthorship W4317778918A5044876586 @default.
- W4317778918 hasAuthorship W4317778918A5045777210 @default.
- W4317778918 hasAuthorship W4317778918A5069828492 @default.
- W4317778918 hasAuthorship W4317778918A5084042135 @default.
- W4317778918 hasBestOaLocation W43177789182 @default.
- W4317778918 hasConcept C118552586 @default.
- W4317778918 hasConcept C121608353 @default.
- W4317778918 hasConcept C126322002 @default.
- W4317778918 hasConcept C142724271 @default.
- W4317778918 hasConcept C159110408 @default.
- W4317778918 hasConcept C168563851 @default.
- W4317778918 hasConcept C17744445 @default.
- W4317778918 hasConcept C177713679 @default.
- W4317778918 hasConcept C1862650 @default.
- W4317778918 hasConcept C197934379 @default.
- W4317778918 hasConcept C199539241 @default.
- W4317778918 hasConcept C204787440 @default.
- W4317778918 hasConcept C27081682 @default.
- W4317778918 hasConcept C27415008 @default.